Why You Might Be Interested In R&G PharmaStudies Co., Ltd. (SZSE:301333) For Its Upcoming Dividend

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that R&G PharmaStudies Co., Ltd. (SZSE:301333) is about to go ex-

Simply Wall StJul 1 19:05 ET

Northeast Securities (301333.SZ) plans to spend 50-80 million yuan to buy back shares.

On July 1st, Gelonhui announced that North Gear (301333.SZ) plans to repurchase its shares for employee stock ownership plans or stock-based incentives. The total amount of funds for repurchasing shares ranges from RMB 50 million (including par value) to RMB 80 million (including par value). The repurchase price does not exceed RMB 58.00 per share (including par value). The implementation period for the repurchase of shares shall not exceed 12 months from the date of approval of the repurchase plan by the board of directors.

Gelonghui FinanceJul 1 04:40 ET

Norstec (301333.SZ) annual equity distribution in 2023: 2 yuan per 10 shares, registered on July 4th.

Norseldge (301333.SZ) announced that the company's annual equity distribution plan for 2023 is: based on the company's existing total share capital, a cash dividend of RMB 2 yuan for every 10 shares will be distributed to all shareholders (including taxes). The registration date for this equity distribution is July 4, 2024, and the ex-dividend date is July 5, 2024.

Zhitong FinanceJun 27 07:49 ET

Nuo Sigge (301333.SZ): There is currently no research on combating HIV and no relevant cooperation with Gilead at present.

On June 24th, Gelonhui reported that Norseg (301333.SZ) stated on the investor interaction platform that the company is currently not conducting research on combating HIV and there is no relevant cooperation with Gilead.

Gelonghui FinanceJun 24 06:03 ET

R&G PharmaStudies Co., Ltd.'s (SZSE:301333) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

With its stock down 19% over the past month, it is easy to disregard R&G PharmaStudies (SZSE:301333). But if you pay close attention, you might find that its key financial indicators look quite dece

Simply Wall StJun 7 00:44 ET

Pacific Securities: The pharmaceutical industry is under short-term pressure, and future policies will be frequent or enhance the certainty of clinical CRO benefits

With the end of the Fed's interest rate hike cycle, gradual easing of liquidity is expected to bring about a recovery in investment and financing, and overseas demand will improve ahead of local demand; future innovative drug support policies may be introduced intensively, and clinical CRO benefits are highly certain.

Zhitong FinanceMay 22 23:24 ET